<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1900-9607</journal-id>
<journal-title><![CDATA[CES Medicina Veterinaria y Zootecnia]]></journal-title>
<abbrev-journal-title><![CDATA[Ces. Med. Vet. Zootec.]]></abbrev-journal-title>
<issn>1900-9607</issn>
<publisher>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1900-96072014000200012</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Canine transmissible venereal tumor: expression of MDR-1, and TP53 and BCL-2 family genes and its implications in biological and therapeutic behavior]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tumor venéreo transmissível canino/: expressão dos genes MDR-1, TP53 e da família Bcl-2 e suas implicações no comportamento biológico e terapêutico]]></article-title>
<article-title xml:lang="es"><![CDATA[Tumor venéreo transmisible canino: expresión de los genes MDR-1, TP53 y de la familia Bcl-2 y sus implicaciones en el comportamiento biológico y terapéutico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoya Floréz]]></surname>
<given-names><![CDATA[Luis Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ballestero Fêo]]></surname>
<given-names><![CDATA[Haline]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa Rocha]]></surname>
<given-names><![CDATA[Noeme]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade Estadual Paulista  ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade Estadual Paulista  ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Universidade Estadual Paulista  ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2014</year>
</pub-date>
<volume>9</volume>
<numero>2</numero>
<fpage>281</fpage>
<lpage>294</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S1900-96072014000200012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S1900-96072014000200012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S1900-96072014000200012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Transmissible venereal tumor (TVT) is a neoplasm of round cells with plasmocytoid or lymphocytoid appearance. The tumor presents several particularities, which have been the subject of numerous studies; however there still have investigations that need to be done. For example, a progressive increase of highly aggressive tumors with varying response to chemotherapy -including resistance- has been evidenced in recent years. There is scientific interest to understand these differences, allowing predicting possible clinical outcomes in affected dogs and increasingly searching adequate and individualized therapy. This review focuses on presenting possible implications of the expression of MDR-1 (P-glycoprotein), TP53, BCL-2, and BAX genes, regarding resistance to chemotherapy and/or the biologic behavior of TVT]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[O tumor venéreo transmissível (TVT) é uma neoplasia de células redondas de aspecto plasmocitóide ou linfocitóide. O tumor apresenta várias particularidades que tem sido objeto de numerosas investigações e apesar disso, ainda existem lacunas que necessitam de maiores estudos. Por exemplo, nos últimos anos, tem-se evidenciado um aumento progressivo de tumores que apresentam elevados porcentuais de agressividade e variável resposta à quimioterapia, inclusive resistência. Desta forma, atualmente há interesses científicos com relação a compreender melhor estas diferenças, permitindo predizer uma possível evolução clínica entre cães acometidos pelo tumor e buscando cada vez mais uma conduta terapêutica adequada e individualizada. Assim, a revisão de literatura, centra-se em apresentar possíveis implicações da expressão dos genes MDR-1 (glicoproteína-p), TP53, BCL-2, BAX, quanto à resistência à quimioterapia, e/ou comportamento biológico do TVT.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[El tumor venéreo transmisible (TVT) es una neoplasia de células redondas de aspecto plasmocitoide o linfocitoide. El tumor presenta varias particularidades que han sido objeto de numerosas investigaciones y a pesar de eso, aún existen algunos vacíos en su conocimiento que requieren mayores estudios. Por ejemplo, en los últimos años, se ha evidenciado un aumento progresivo de tumores que presentan elevados porcentajes de agresividad y una respuesta variable a la quimioterapia, inclusive alguna resistencia. En este sentido, actualmente hay intereses científicos con relación a comprender mejor estas diferencias, permitiendo predecir una posible evolución clínica entre perros afectados por el tumor y buscando cada vez más una conducta terapéutica adecuada e individualizada. Así, la revisión de literatura, se centra en presentar posibles implicaciones de la expresión de los genes MDR-1 (glicoproteína-p), TP53, BCL-2, BAX, en cuanto a la resistencia a la quimioterapia, y/o el comportamiento biológico del TVT]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Cytology]]></kwd>
<kwd lng="en"><![CDATA[chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[radiotherapy]]></kwd>
<kwd lng="en"><![CDATA[vincristine]]></kwd>
<kwd lng="pt"><![CDATA[Citologia]]></kwd>
<kwd lng="pt"><![CDATA[quimioterapia]]></kwd>
<kwd lng="pt"><![CDATA[radioterapia]]></kwd>
<kwd lng="pt"><![CDATA[vincristina]]></kwd>
<kwd lng="es"><![CDATA[Citología]]></kwd>
<kwd lng="es"><![CDATA[quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[radioterapia]]></kwd>
<kwd lng="es"><![CDATA[vincristina]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  <font face="verdana" size="2">     <p align="center"><font size="4"><b>Canine transmissible venereal tumor: expression of <I>MDR-1</I>, and <I>TP53</I> and <I>BCL-2</I> family genes and its implications in biological and therapeutic behavior</b></font><Sup>&curren;</Sup></p>     <p align="center"><font size="3"><b><I>Tumor ven&eacute;reo transmiss&iacute;vel canino: express&atilde;o dos genes MDR-1, TP53 e da fam&iacute;lia Bcl-2 e suas implica&ccedil;&otilde;es no comportamento biol&oacute;gico e terap&ecirc;utico</I></b></font></p>     <p align="center"><font size="3"><b><I>Tumor ven&eacute;reo transmisible canino: expresi&oacute;n de los genes MDR-1, TP53 y de la familia Bcl-2 y sus implicaciones en el comportamiento biol&oacute;gico y terap&eacute;utico</I></b></font></p>     <p align="center">Luis Mauricio Montoya Flor&eacute;z<Sup>1</Sup>, MSc; Haline Ballestero F&ecirc;o<Sup>2</Sup>, MSc; Noeme Sousa Rocha<Sup>3</Sup>, PhD.</p>     <p><Sup>&curren;</Sup>Para citar este art&iacute;culo: Montoya Fl&oacute;rez LM, Ballestero F&ecirc;o H, Sousa Rocha N. Tumor ven&eacute;reo transmiss&iacute;vel canino: express&atilde;o dos genes MDR-1, TP53 e da fam&iacute;lia Bcl-2 e suas implica&ccedil;&otilde;es no comportamento biol&oacute;gico e terap&ecirc;utico . Rev CES Med Zootec. 2014; Vol 9(2): 281-294.</p>     <p><I>*Autor para correspondencia: Luis Mauricio Montoya Flor&eacute;z. Universidad de Caldas.  <a href="mailto:maomontoya53@yahoo.es">maomontoya53@yahoo.es</a> </I></p>     <p><Sup> 1</Sup>Mestrado na Universidade de Caldas, Manizales, Colombia. Grupo de pesquisa em Patologia Veterin&aacute;ria, Departamento de Cl&iacute;nica Veterin&aacute;ria, FMVZ, Universidade Estadual Paulista, Botucatu, S&atilde;o Paulo, Brasil.    <br> <Sup>2</Sup> Mestrado na Universidade Estadual de Campinas. Grupo de pesquisa em Patologia Veterin&aacute;ria, Departamento de Cl&iacute;nica Veterin&aacute;ria, FMVZ, Universidade Estadual Paulista, Botucatu, S&atilde;o Paulo, Brasil.    <br> <Sup>3</Sup> Doutorado e livre-doc&ecirc;ncia na Universidade Estadual Paulista Julio de Mesquita Filho. Grupo de pesquisa em Patologia Veterin&aacute;ria, Departamento de Cl&iacute;nica Veterin&aacute;ria, FMVZ, Universidade Estadual Paulista, Botucatu, S&atilde;o Paulo, Brasil.</p>     ]]></body>
<body><![CDATA[<p align="center"><I>(Recibido: 13 de mayo, 2014; aceptado: 18 de septiembre, 2014)</I></p> <hr>     <p><b>Abstract</b></p>     <p>Transmissible venereal tumor (TVT) is a neoplasm of round cells with plasmocytoid or lymphocytoid appearance. The tumor presents several particularities, which have been the subject of numerous studies; however there still have investigations that need to be done. For example, a progressive increase of highly aggressive tumors with varying response to chemotherapy -including resistance- has been evidenced in recent years. There is scientific interest to understand these differences, allowing predicting possible clinical outcomes in affected dogs and increasingly searching adequate and individualized therapy. This review focuses on presenting possible implications of the expression of <I>MDR-1</I> (P-glycoprotein), <I>TP53</I>, <I>BCL-2</I>, and <I>BAX</I> genes, regarding resistance to chemotherapy and/or the biologic behavior of TVT.</p>     <p><b>Key words</b>: <I>Cytology, chemotherapy, radiotherapy, vincristine. </I></p> <hr>     <p><b>Resumo</b></p>     <p>O tumor ven&eacute;reo transmiss&iacute;vel (TVT) &eacute; uma neoplasia de c&eacute;lulas redondas de aspecto plasmocit&oacute;ide ou linfocit&oacute;ide. O tumor apresenta v&aacute;rias particularidades que tem sido objeto de numerosas investiga&ccedil;&otilde;es e apesar disso, ainda existem lacunas que necessitam de maiores estudos. Por exemplo, nos &uacute;ltimos anos, tem-se evidenciado um aumento progressivo de tumores que apresentam elevados porcentuais de agressividade e vari&aacute;vel resposta &agrave; quimioterapia, inclusive resist&ecirc;ncia. Desta forma, atualmente h&aacute; interesses cient&iacute;ficos com rela&ccedil;&atilde;o a compreender melhor estas diferen&ccedil;as, permitindo predizer uma poss&iacute;vel evolu&ccedil;&atilde;o cl&iacute;nica entre c&atilde;es acometidos pelo tumor e buscando cada vez mais uma conduta terap&ecirc;utica adequada e individualizada. Assim, a revis&atilde;o de literatura, centra-se em apresentar poss&iacute;veis implica&ccedil;&otilde;es da express&atilde;o dos genes <I>MDR-1</I> (glicoprote&iacute;na-p), <I>TP53, BCL-2, BAX</I>, quanto &agrave; resist&ecirc;ncia &agrave; quimioterapia, e/ou comportamento biol&oacute;gico do TVT.</p>     <p><b>Palavras-chave</b>: <I>Citologia, quimioterapia, radioterapia, vincristina. </I></p> <hr>     <p><b>Resumen</b></p>     <p>El tumor ven&eacute;reo transmisible (TVT) es una neoplasia de c&eacute;lulas redondas de aspecto plasmocitoide o linfocitoide. El tumor presenta varias particularidades que han sido objeto de numerosas investigaciones y a pesar de eso, a&uacute;n existen algunos vac&iacute;os en su conocimiento que requieren mayores estudios.  Por ejemplo, en los &uacute;ltimos a&ntilde;os, se ha evidenciado un aumento progresivo de tumores que presentan elevados porcentajes de agresividad y una respuesta variable a la quimioterapia, inclusive alguna resistencia. En este sentido, actualmente hay intereses cient&iacute;ficos con relaci&oacute;n a comprender mejor estas diferencias, permitiendo predecir una posible evoluci&oacute;n cl&iacute;nica entre perros afectados por el tumor y buscando cada vez m&aacute;s una conducta terap&eacute;utica adecuada e individualizada. As&iacute;, la revisi&oacute;n de literatura, se centra en presentar posibles implicaciones de la expresi&oacute;n de los genes <I>MDR-1</I> (glicoprote&iacute;na-p), <I>TP53, BCL-2, BAX</I>, en cuanto a la resistencia a la quimioterapia, y/o el comportamiento biol&oacute;gico del TVT.</p>     <p><b>Palabras clave</b>: <I>Citolog&iacute;a, quimioterapia, radioterapia, vincristina.</I></p> <hr>     ]]></body>
<body><![CDATA[<p><b>Introdu&ccedil;&atilde;o</b></p>     <p>O tumor ven&eacute;reo transmiss&iacute;vel (TVT) &eacute; uma neoplasia de origem incerta. No entanto, quanto &agrave; morfologia, o tumor &eacute; classificado como uma neoplasia de c&eacute;lulas redondas com aspecto plasmocit&oacute;ide ou linfocit&oacute;ide <Sup>4</Sup>. O seu relato na literatura especializada diz que o TVT emergiu faz dez mil anos <Sup>48, 58</Sup> e sua distribui&ccedil;&atilde;o &eacute; mundial <Sup>3, 19, 54</Sup>. </p>      <p>O tumor apresenta algumas particularidades, como o acometimento da esp&eacute;cie canina <Sup>21, 49, 50</Sup> e uma agressividade question&aacute;vel, pois dificilmente esta se correlaciona com o &oacute;bito do paciente <Sup>58</Sup>. </p>      <p>O TVT implanta-se pelo contato de suas c&eacute;lulas vi&aacute;veis com as mucosas que perderam sua integridade, sendo a transmiss&atilde;o ven&eacute;rea a mais frequente <Sup>21, 50</Sup>. Quando implantado, o tumor reduz o mecanismo de defesa do animal, apresenta-se de forma &uacute;nica ou m&uacute;ltipla e localiza-se preferencialmente na mucosa da genit&aacute;lia externa, al&eacute;m das narinas, da cavidade oral, ocular e da pele. Em casos menos frequentes pode invadir tecidos distantes do s&iacute;tio prim&aacute;rio, como mama, pulm&atilde;o, ba&ccedil;o, enc&eacute;falo e outros &oacute;rg&atilde;os <Sup>19, 21, 30</Sup>.</p>      <p>A neoplasia geralmente se apresenta em forma de massas com consist&ecirc;ncia fri&aacute;vel que sangram facilmente <Sup>21, 56</Sup>. O diagn&oacute;stico &eacute; feito com base no hist&oacute;rico do animal, no exame cl&iacute;nico, al&eacute;m dos exames complementares de citologia e de histopatologia <Sup>15, 21</Sup>. O exame de citologia, seja por pun&ccedil;&atilde;o ou esfolia&ccedil;&atilde;o, &eacute; o mais utilizado para o diagn&oacute;stico, al&eacute;m de permitir classifica-lo em tumor de c&eacute;lulas redondas, do tipo linfocit&oacute;ide, plasmocit&oacute;ide ou misto <Sup>4, 42</Sup>.</p>      <p>Nos casos de dificuldade no diagn&oacute;stico, podem ser realizadas an&aacute;lises cromoss&ocirc;micas e de imunofenotipagem <Sup>70</Sup>. Nesse caso, o TVT pode ser identificado pela presen&ccedil;a de lisozima e alfa antitripsina (ATT), que se encontram expressas respectivamente em 40% e 52% dos tumores em c&atilde;es <Sup>44</Sup>. Al&eacute;m disso, pode-se se identificar o tumor ainda pela express&atilde;o da vimentina e pelo MAC1, que &eacute; um marcador de macr&oacute;fagos <Sup>35</Sup>.</p>      <p>No protocolo terap&ecirc;utico estabelecido para o TVT, utiliza-se o sulfato de vincristina como agente &uacute;nico, em aplica&ccedil;&otilde;es semanais (quatro a oito aplica&ccedil;&otilde;es via intravenosa), sendo esse protocolo o mais utilizado para a regress&atilde;o do tumor <Sup>17, 21, 50</Sup>. Dessa forma, cerca de 90% dos c&atilde;es submetidos a esse tratamento respondem satisfatoriamente, embora apresentem sinais sugestivos de efeitos colaterais graves, o que leva &agrave; interrup&ccedil;&atilde;o do tratamento <Sup>6</Sup>. </p>      <p>Apenas um pequeno percentual de tumores &eacute; resistente &agrave; vincristina <Sup>53, 55</Sup>. Nesse caso, os f&aacute;rmacos de escolha s&atilde;o a doxorrubicina ou ciclofosfamina <Sup>53</Sup> e com menor frequ&ecirc;ncia a vimblastina, metrotexate, prednisolona ou suas combina&ccedil;&otilde;es <Sup>28, 64</Sup>. Portanto, atualmente, a terapia para o TVT restringe-se a um escasso n&uacute;mero de drogas que &agrave;s vezes acabam n&atilde;o sendo suficientes, pois existem tumores que apresentam resist&ecirc;ncia a essas drogas <Sup>5, 6, 61</Sup>.</p>      <p>Em pesquisas desenvolvidas, no Laborat&oacute;rio de Patologia Veterin&aacute;ria Comparada da UNESP-Botucatu, tem-se evidenciado um aumento progressivo de tumores que apresentam elevados porcentuais de agressividade e vari&aacute;vel resposta &agrave; quimioterapia, inclusive resist&ecirc;ncia. Isso em parte ocorre devido &agrave; elevada express&atilde;o de glicoprote&iacute;na-p pelas c&eacute;lulas tumorais o que acarreta expuls&atilde;o do quimioter&aacute;pico <Sup>24</Sup>. Assim, h&aacute; uma eleva&ccedil;&atilde;o em rela&ccedil;&atilde;o aos custos do tratamento, al&eacute;m dos efeitos colaterais tais como: anorexia, mielosupress&atilde;o e nefrotoxicidade.</p>      <p>Em pesquisas t&ecirc;m-se observado padr&otilde;es morfol&oacute;gicos e moleculares que s&atilde;o pr&oacute;prios de tumores mais agressivos <Sup>2, 43</Sup>, por&eacute;m precisa-se conhecer ainda a associa&ccedil;&atilde;o destes padr&otilde;es com o comportamento biol&oacute;gico, ou seja com a agressividade, num poss&iacute;vel progn&oacute;stico, assim como com a resist&ecirc;ncia ao tratamento. </p>      ]]></body>
<body><![CDATA[<p>A resist&ecirc;ncia &agrave; terapia e o comportamento biol&oacute;gico vari&aacute;vel nos tumores s&atilde;o fen&ocirc;menos multifatoriais. Dentre alguns fen&ocirc;menos que geralmente regulam esses processos, podemos citar genes pro e antiapopt&oacute;ticos da fam&iacute;lia <I>BCL-2</I>, mecanismos de detoxifica&ccedil;&atilde;o intracelular e super-express&atilde;o de mol&eacute;culas que transportam as drogas para fora da c&eacute;lula ou para outros compartimentos celulares, como a glicoprote&iacute;na-p (produto do gene <I>MDR-1</I>); al&eacute;m de sistemas de reparo do DNA associados com a fam&iacute;lia do <I>TP53</I>.</p>     <p>Dessa forma, considerando a import&acirc;ncia em aprofundar a compress&atilde;o da evolu&ccedil;&atilde;o e patogenicidade do TVT, a revis&atilde;o visa descrever as poss&iacute;veis implica&ccedil;&otilde;es da express&atilde;o dos genes <I>MDR-1</I> (glicoprote&iacute;na-p), <I>TP53, BCL-2, BAX, </I>quanto &agrave; resist&ecirc;ncia &agrave; quimioterapia, ou ao comportamento biol&oacute;gico do TVT. </p>     <p><b>Resist&ecirc;ncia mediada pelo gene MDR1 (glicoprote&iacute;na-p)</b></p>     <p>Normalmente, a resist&ecirc;ncia &agrave; quimioterapia &eacute; um grande obst&aacute;culo para os pacientes com c&acirc;ncer. Para sua explica&ccedil;&atilde;o, muitos mecanismos t&ecirc;m sido propostos, por&eacute;m, o principal processo envolvido na resist&ecirc;ncia cl&iacute;nica &agrave; quimioterapia, &eacute; a super-express&atilde;o da glicoprote&iacute;na-p (Pgp) na membrana da c&eacute;lula. A Pgp reconhece diferentes agentes quimioter&aacute;picos e os transporta para fora da c&eacute;lula, levando as drogas a uma redu&ccedil;&atilde;o da concentra&ccedil;&atilde;o intracelular, at&eacute; n&iacute;veis n&atilde;o letais <Sup>9, 27, 69</Sup>. </p>      <p>Quanto ao TVT, nos &uacute;ltimos anos se tem registrado um crescente percentual de animais resistentes &agrave; quimioterapia,<Sup>6,23,24</Sup> com severas implica&ccedil;&otilde;es, principalmente porque &agrave; terapia atualmente restringe-se a um escasso n&uacute;mero de drogas <Sup>53, 55</Sup>. Desta forma, na procura de explica&ccedil;&otilde;es sobre a vari&aacute;vel resposta terap&ecirc;utica, foi sugerido que altera&ccedil;&otilde;es na express&atilde;o da Pgp em c&eacute;lulas do tumor, tinham associa&ccedil;&atilde;o com resist&ecirc;ncia &agrave; vincristina, droga de principal escolha para o tratamento do TVT.</p>      <p>Em nossos estudos, quando analisamos os resultados da marca&ccedil;&atilde;o com o anticorpo antiglicoprote&iacute;na-p, verificamos que TVTs com morfologia  plasmocit&oacute;ide apresentaram uma imunorreatividade significativamente maior em rela&ccedil;&atilde;o com a morfologia linfocit&oacute;ide. Portanto, podemos considerar que o primeiro subtipo apresenta um potencial para expressar resist&ecirc;ncia &agrave; droga (<a href="#t1">Tabela 1</a>) <Sup>22</Sup>.</p>     <p align="center"><a name="t1"></a><img src="img/revistas/cmvz/v9n2/v9n2a12t1.jpg"></p>     <p>Analisando as respostas cl&iacute;nicas &agrave; quimioterapia, observou-se que TVTs plasmocit&oacute;ides foram menos sens&iacute;vel &agrave; quimioterapia em rela&ccedil;&atilde;o aos grupos linfocit&oacute;ide, mostrando diferen&ccedil;a significativa. Quando esta resposta foi comparada com a express&atilde;o de glicoprote&iacute;na-p, observou-se uma rela&ccedil;&atilde;o direta da resposta parcial a quimioterapia com uma forte express&atilde;o de glicoprote&iacute;na-p no grupo plasmocit&oacute;ide <Sup>22</Sup>. Pode-se inferir portanto, que casos cl&iacute;nicos de TVT do tipo plasmocit&oacute;ide tendem a apresentar resposta cl&iacute;nica parcial &agrave; quimioterapia, possivelmente pela forte express&atilde;o de glicoprote&iacute;na-p. Da mesma forma, tumores do tipo linfocit&oacute;ide t&ecirc;m resposta completa &agrave; quimioterapia, provavelmente pela baixa express&atilde;o de glicoprote&iacute;na-p (<a href="#t2">Tabela 2</a>) <Sup>22</Sup>.</p>     <p align="center"><a name="t2"></a><img src="img/revistas/cmvz/v9n2/v9n2a12t2.jpg"></p>     <p>De forma geral, a express&atilde;o imunoistoqu&iacute;mica da Pgp &eacute; vari&aacute;vel no TVT, e descreve-se maior resist&ecirc;ncia &agrave; quimioterapia em tumores com superexpress&atilde;o dessa prote&iacute;na <Sup>22, 23, 24</Sup>, resultado em concord&acirc;ncia com o j&aacute; descrito em tumores de humanos. </p>      ]]></body>
<body><![CDATA[<p>A Pgp, tamb&eacute;m conhecida como ABCB1 &eacute; o produto do gene MDR-1. Trata-se de uma prote&iacute;na de 170 kDa, com 12 dom&iacute;nios trans-membrana e dois s&iacute;tios de uni&atilde;o ao ATP. A Pgp pertence a fam&iacute;lia das prote&iacute;nas ABC (<I>ATP-</I> <I>binding cassette</I>), que s&atilde;o prote&iacute;nas canais de membrana dependentes de energia e est&atilde;o envolvidos na transfer&ecirc;ncia de mol&eacute;culas biol&oacute;gicas atrav&eacute;s da membrana contra um gradiente de concentra&ccedil;&atilde;o, com alta express&atilde;o em tecidos tumorais previamente expostos a f&aacute;rmacos <Sup>27, 39, 59</Sup>. A Pgp pode ainda induzir multirresist&ecirc;ncia a drogas <Sup>66</Sup>.</p>      <p>Essa prote&iacute;na &eacute; expressa em c&eacute;lulas normais das adrenais, rins, f&iacute;gado, c&oacute;lon, c&eacute;rebro, pulm&otilde;es, sangue perif&eacute;rico e na medula &oacute;ssea <Sup>67</Sup>. A Pgp funciona como bomba de efluxo dependente de energia, gerada pela hidr&oacute;lise do ATP <Sup>36, 67</Sup>. Em condi&ccedil;&otilde;es normais, atua defendendo a c&eacute;lula contra agentes citot&oacute;xicos e transportando drogas para o seu exterior, como a doxorrubicina, dianorrubicina, epirrubicina, vincristina, vimblastina, vinorelbina, otoposide, opotecan, entre outras <Sup>59</Sup>, reduzindo as concentra&ccedil;&otilde;es a n&iacute;veis n&atilde;o letais <Sup>67, 36</Sup>. </p>      <p>Apesar do mecanismo protetor, a sua super-express&atilde;o leva &agrave; multirresist&ecirc;ncia a drogas <Sup>69</Sup>. Al&eacute;m disso, a Pgp tamb&eacute;m transporta subst&acirc;ncias que atuam no crescimento da c&eacute;lula <Sup>66</Sup>, e h&aacute; observa&ccedil;&otilde;es que sustentam a possibilidade da Pgp promover sobrevida da c&eacute;lula por vias independentes ao efluxo de subst&acirc;ncias, que incluem a inibi&ccedil;&atilde;o das caspases na via de apoptoses <Sup>74</Sup>.</p>      <p>Em associa&ccedil;&atilde;o, quando existe superexpress&atilde;o do <I>MDR-1,</I> observa se tamb&eacute;m, expressiva influ&ecirc;ncia nos mecanismos de apoptose nas c&eacute;lulas tumorais. Esse mecanismo &eacute; aceito como de preven&ccedil;&atilde;o, onde consequentemente o n&uacute;mero de c&eacute;lulas s&atilde;o mantidas <Sup>73</Sup>. Outros pesquisadores que investigam o fen&ocirc;meno, acreditam que o <I>MDR-1</I> atua por meio de uma variedade de est&iacute;mulos, dentre eles a inibi&ccedil;&atilde;o via TNF, Fas e irradia&ccedil;&atilde;o gama <Sup>9, 34 </Sup>(<a href="#g1">Gr&aacute;fico 1</a>).</p>     <p align="center"><a name="g1"></a><img src="img/revistas/cmvz/v9n2/v9n2a12g1.jpg"></p>     <p>Em oncologia m&eacute;dica, a import&acirc;ncia cl&iacute;nica da resist&ecirc;ncia a multidrogas &eacute; demonstrada pelos n&iacute;veis elevados de express&atilde;o de Pgp. Como consequ&ecirc;ncia, h&aacute; aus&ecirc;ncia de resposta &agrave; quimioterapia <Sup>39</Sup>, progn&oacute;stico ruim e reduzido tempo de sobrevida <Sup>9</Sup>.  Maia e Rumjanek <Sup>36 </Sup>descreveram que um n&uacute;mero significativo de pacientes que apresentavam resist&ecirc;ncia &agrave; quimioterapia, expressavam altas quantidades de Pgp.</p>      <p>Entretanto, estudos desenvolvidos por Mochida <I>et al</I>. <Sup>41</Sup>, demostraram que a aus&ecirc;ncia da Pgp, suprimiu o aparecimento de neoplasia intestinal em camundongo. Por&eacute;m, a aus&ecirc;ncia da express&atilde;o da Pgp &eacute; controversa, pois a altera&ccedil;&atilde;o dos mecanismos mediados pela glicoprote&iacute;na podem conduzir a maior exposi&ccedil;&atilde;o a agentes t&oacute;xicos, levando a  incrementar o risco para desenvolver v&aacute;rios tipos de c&acirc;ncer de diferentes malignidades, de forma que essa rela&ccedil;&atilde;o casual ainda tem que ser melhor estudada <Sup>73</Sup>.</p>      <p>Apesar desses estudos n&atilde;o serem atuais, eles trazem informa&ccedil;&otilde;es relevantes para a compreens&atilde;o de resist&ecirc;ncia a quimioter&aacute;picos, em especial no estabelecimento do protocolo para o TVT, visto que, s&atilde;o escassos os estudos para esse fim. De acordo com Mealey <I>et al</I>. <Sup>37</Sup>, a Pgp em c&atilde;es com linfoma funciona de forma similar ao homem. Nesse caso, os autores demonstraram nas suas pesquisas que os n&iacute;veis de Pgp tiveram maiores express&otilde;es na recidiva, do que at&eacute; mesmo no momento do diagn&oacute;stico prim&aacute;rio. De fato, h&aacute; correla&ccedil;&atilde;o entre a express&atilde;o da Pgp e o comportamento do tumor, visto que h&aacute; interfer&ecirc;ncia na remiss&atilde;o e no tempo de sobrevida <Sup>8</Sup>.</p>      <p>Lee <I>et al</I>. <Sup>33</Sup> demonstraram que a express&atilde;o inicial de Pgp nos linfomas de c&atilde;o &eacute; menor do que ap&oacute;s a recidiva do tumor. Concluiu-se dessa forma, que a express&atilde;o da Pgp antes do in&iacute;cio do tratamento &eacute; um fator preditivo independente e negativo de sobreviv&ecirc;ncia. </p>     <p>Diante do exposto, a extrapola&ccedil;&atilde;o do estudo da express&atilde;o da Pgp e sua rela&ccedil;&atilde;o  com uma poss&iacute;vel resist&ecirc;ncia &agrave; quimioterapia pode trazer benef&iacute;cios para o animal acometido com o TVT. Al&eacute;m do mais, ajudariam com informa&ccedil;&otilde;es relevantes para a compreens&atilde;o de mecanismos de resist&ecirc;ncia do tumor, al&eacute;m de estimular pesquisas para uma poss&iacute;vel modula&ccedil;&atilde;o da express&atilde;o do gene <I>MDR-1</I> em caninos.</p>     ]]></body>
<body><![CDATA[<p><b>Resist&ecirc;ncia e agressividade tumoral mediada pela express&atilde;o do gene <i>TP53</i></b></p>     <p>O <I>TP53</I> &eacute; um dos genes que mais frequentemente sofrem muta&ccedil;&atilde;o no c&acirc;ncer de humanos. T&ecirc;m-se relatado que aproximadamente a metade de todos os tumores tem altera&ccedil;&atilde;o do <I>TP53</I> <Sup>60</Sup>; al&eacute;m de haver evid&ecirc;ncias de que a express&atilde;o de <I>MDR-1</I>, ou seja Pgp, &eacute; regulada por certos mutantes da prote&iacute;na p53, sugerindo que a resposta &agrave; quimioterapia ou radioterapia pode depender em parte ao estado do <I>TP53 </I>antes do tratamento <Sup>45</Sup>.</p>      <p>O gene <I>TP53 </I>localiza-se no bra&ccedil;o curto do cromossomo humano 17 (17p13) e cont&eacute;m 11 exons que compreendem a 20 Kb <Sup>51</Sup>. O gene codifica a forma&ccedil;&atilde;o do p53, uma fosfoprote&iacute;na nuclear de 53 KDa composta por 393 amino&aacute;cido<I>. </I>Esta prote&iacute;na foi descoberta na d&eacute;cada de 1970, em preparados de c&eacute;lulas SV40 e t&ecirc;m implica&ccedil;&otilde;es no ciclo celular, no reparo e s&iacute;ntese de DNA, diferencia&ccedil;&atilde;o celular, plasticidade gen&ocirc;mica e no programa de morte celular <Sup>25, 65</Sup>.</p>      <p>A muta&ccedil;&atilde;o do <I>TP53 </I>foi descrita em c&atilde;es <Sup>29</Sup> na presen&ccedil;a do TVT. Choi e Kim <Sup>14</Sup> descreveram os primeiros relatos de muta&ccedil;&atilde;o do gene. Achados corroboraram em estudos posteriores, desenvolvidos por Serv&iacute;n <I>et al</I>. <Sup>57</Sup>. Por&eacute;m, apesar das evid&ecirc;ncias de muta&ccedil;&atilde;o do gene no tumor, se desconhece se esta particularidade gera alguma troca na fun&ccedil;&atilde;o da prote&iacute;na <Sup>71</Sup>.</p>      <p>De acordo com Serv&iacute;n <I>et al</I>. <Sup>57</Sup>,  ainda &eacute; preciso estabelecer a fun&ccedil;&atilde;o que  pode desempenhar os polimorfismos do <I>TP53 </I> na patog&ecirc;neses e resposta &agrave; quimioterapia no TVT. Stockmann <I>et al</I>. <Sup>62</Sup>, assim como S&eacute;rvin <I>et al. </I><Sup>57</Sup>, enfatizam a necessidade de avaliar os efeitos da express&atilde;o da prote&iacute;na, e dos membros de sua fam&iacute;lia nas c&eacute;lulas do TVT, relacionando os achados com o progn&oacute;stico e poss&iacute;veis alternativas terap&ecirc;uticas. Al&eacute;m disso, &eacute; preciso determinar a influencia do hospedeiro sobre esta express&atilde;o.</p>      <p>Em trabalhos desenvolvidos pelo nosso grupo, nos que foram utilizadas  culturas prim&aacute;rias de c&eacute;lulas de TVT, constatou-se que c&eacute;lulas que recebiam tratamento com vincristina, apresentavam baixa taxa de express&atilde;o do p53, quando comparadas com c&eacute;lulas que n&atilde;o recebiam. Neste caso sugeriu-se, como uma poss&iacute;vel explica&ccedil;&atilde;o, uma regula&ccedil;&atilde;o da express&atilde;o da prote&iacute;na pelo tumor, promovendo sua diminui&ccedil;&atilde;o como poss&iacute;vel forma de se proteger da entrada em apoptose (dados ainda n&atilde;o publicados). </p>     <p>Em regra, em tecidos normais, o n&iacute;vel de express&atilde;o do <I>TP53</I> &eacute; extremamente baixo. Em resposta a m&uacute;ltiplos fatores que podem afetar a c&eacute;lula, como a ativa&ccedil;&atilde;o de oncogenes, hip&oacute;xia, desregula&ccedil;&atilde;o de nucleot&iacute;deos e danos oxidativos, o p53 &eacute; rapidamente acumulado no n&uacute;cleo por modifica&ccedil;&otilde;es qu&iacute;micas como fosforila&ccedil;&atilde;o e acetila&ccedil;&atilde;o, exercendo sua fun&ccedil;&atilde;o pr&oacute;-apot&oacute;tica e removendo assim, c&eacute;lulas com s&eacute;rios danos no DNA <Sup>51 </Sup>(<a href="#g2">Gr&aacute;fico 2</a>).</p>     <p align="center"><a name="g2"></a><img src="img/revistas/cmvz/v9n2/v9n2a12g2.jpg"></p>     <p>Neste caso, a p53 ativa alvos pr&oacute;-apot&oacute;ticos como a Bax, PUMA, NOXA e p53APA1 que, em conjunto, contribuem para &agrave; desestabiliza&ccedil;&atilde;o do potencial de membrana mitocondrial que &eacute; um passo cr&iacute;tico da via da apoptose <Sup>12, 32</Sup>. Assim, o p53 &eacute; um importante regulador da apoptose. Ele interage com prote&iacute;nas pr&oacute; e antiapopt&oacute;ticas como a Bcl-2 <Sup>40, 65, 68</Sup>, e como foi dito com o Bax<Sup>51, 65</Sup>, al&eacute;m de existir evid&ecirc;ncias de que ela tamb&eacute;m regule a apoptose independente da transcri&ccedil;&atilde;o mitocondrial mediante os membros da fam&iacute;lia Bcl-2 <Sup>11, 20</Sup>. Da mesma forma, o p53 pode transativar genes como <I>BAX, </I>resultando em um alto potencial para induzir apoptoses em c&eacute;lulas tumorais <Sup>38</Sup>.</p>      <p>Por&eacute;m, a p53 n&atilde;o s&oacute; induz apoptoses, mas tamb&eacute;m participa nas demais fases do ciclo celular. Na fase G1, a p53 participa atrav&eacute;s da transativa&ccedil;&atilde;o do p21, enquanto que na fase G2/M ela bloqueia a entrada da c&eacute;lula &agrave; mitose. O mecanismo dual da p53 no comportamento protetor e indutor da apoptose, indicam que o gene pode atuar como promotor de tumor, pois a p53 pode levar a maior sobrevida de c&eacute;lulas com alguma les&atilde;o  e incrementar a possibilidade de transforma&ccedil;&atilde;o maligna <Sup>65</Sup>.</p>      ]]></body>
<body><![CDATA[<p>Do ponto de vista cl&iacute;nico, a inativa&ccedil;&atilde;o ou muta&ccedil;&atilde;o do gene <I>TP53</I> &eacute; um evento molecular frequente e grave para a maioria dos tumores; pois existem formas mutantes do <I>TP53 </I>que exibem tempos de vida m&eacute;dia mais longa, com potencial oncog&ecirc;nico e efeitos negativos sobre os tipos originais levando &agrave; quimioresist&ecirc;ncia <Sup>51</Sup>. Algumas inclusive, ocasionam transativa&ccedil;&atilde;o de genes como <I>EGFR, C-MYC</I> e o <I>MDR-1 </I><Sup>10 </Sup>demonstrando diferentes a&ccedil;&otilde;es das formas mutantes da <I>TP53 </I><Sup>47, 72</Sup>.</p>      <p>Em situa&ccedil;&atilde;o de heterozigose, no qual os tipos de p53 normais e mutantes est&atilde;o presentes, a inativa&ccedil;&atilde;o do p53 por express&atilde;o de mutantes, pode conceder as c&eacute;lulas vantagens para seu crescimento e sobrevida. Isso se d&aacute; de forma a incrementar a sua prolifera&ccedil;&atilde;o e evitar apoptose, gerando quimioresist&ecirc;ncia. A express&atilde;o de mutantes de p53, favorecem ainda, processos como a angiog&ecirc;nese, migra&ccedil;&atilde;o, invas&atilde;o e met&aacute;stase do tumor <Sup>52</Sup>.</p>      <p>Em estudos pr&eacute;vios, desenvolvidos em camundongos com perda do p53 nativo, foi observado que apesar deles apresentarem com maior frequ&ecirc;ncia tumores, estes exibiam uma propor&ccedil;&atilde;o baixa de met&aacute;stase e crescimento invasivo <Sup>(7)</Sup>, quando comparado com camundongos que tinham formas mutantes do p53 <Sup>26</Sup>. Em estudos "<I>in vitro</I>", com comportamento similar do p53, observou-se a mesma condi&ccedil;&atilde;o <Sup>1, 46</Sup>. </p>      <p>Considerando a an&aacute;lise dos aspectos descritos anteriormente e do ponto de vista da oncologia comparada, &eacute; poss&iacute;vel que no TVT, as muta&ccedil;&otilde;es no gene tamb&eacute;m possam impactar de forma direta o seu comportamento cl&iacute;nico, al&eacute;m da agressividade, resist&ecirc;ncia e potencial de met&aacute;stases, como &eacute; observado em outros tumores.</p>     <p><b>Resist&ecirc;ncia e agressividade tumoral mediada pela express&atilde;o dos gene da fam&iacute;lia <i>BCL-2</i></b></p>     <p>Prote&iacute;nas da fam&iacute;lia Bcl-2 foram identificadas em TVT. Stockmann <I>et al</I>. <Sup>62</Sup> demonstraram que no tumor,  a superexpress&atilde;o do Bcl-2 &eacute; independente do seu estagio de desenvolvimento. Anteriormente, Frenzel <I>et al</I>. <Sup>20</Sup> sugeriram  que a superexpress&atilde;o da prote&iacute;na Bcl-2 promoveria a aquisi&ccedil;&atilde;o de fun&ccedil;&otilde;es no tumor associadas &agrave; progress&atilde;o e a sobrevida. Da mesma forma, Amaral <I>et al</I>. <Sup>2 </Sup>destacam que TVT menos agressivos t&ecirc;m alto &iacute;ndice de apoptose e podem at&eacute; apresentar melhor progn&oacute;stico.</p>      <p>Considerando que danos no DNA estimulam a ativa&ccedil;&atilde;o de diversos genes nas vias apopt&oacute;ticas, entre eles os da fam&iacute;lia BCL-2, o nosso grupo utilizou o ensaio do cometa a fim de investigar o n&iacute;vel destes danos em c&eacute;lulas de TVT. Os resultados da pesquisa evidenciaram que tumores em est&aacute;dios iniciais de desenvolvimento denominados de morfologia linfocit&oacute;ide, apresentaram mais les&otilde;es no DNA, que foram estatisticamente diferentes, quando comparados com est&aacute;dios mais tardios de TVTs (plasmocit&oacute;ides) (<a href="#t3">Tabela 3</a>) <Sup>2</Sup>. Assim, estes resultados sugerem comportamento vari&aacute;vel do tumor, sendo que, morfologias do tipo plasmocit&oacute;ide podem apresentar alta agressividade e prolifera&ccedil;&atilde;o, levando a menores taxas de apoptoses, portanto, possivelmente menor express&atilde;o de genes pr&oacute;apototicos <Sup>2</Sup>. </p>     <p align="center"><a name="t3"></a><img src="img/revistas/cmvz/v9n2/v9n2a12t3.jpg"></p>     <p>Os genes <I>BAX</I> e <I>BCL-2</I> pertencem a uma mesma fam&iacute;lia. H&aacute; cerca de 25 genes que codificam prote&iacute;nas que regulam a permeabilidade da membrana externa da mitoc&ocirc;ndria e subdividem-se conforme a sua fun&ccedil;&atilde;o e seu dom&iacute;nio. As prote&iacute;nas podem ser pr&oacute;-apopt&oacute;ticas (Bax, Bad, Bak, Bok, entre outras), anti-apopt&oacute;ticas (Bcl-2 propriamente dito, Bcl-xL e Bcl-w), entre outras <Sup>12, 13, 39</Sup>. </p>      <p>A regula&ccedil;&atilde;o das proteinas da fam&iacute;lia Bcl-2 e as intera&ccedil;&otilde;es com outros membros da sua fam&iacute;lia est&atilde;o bem definidos, assim como muitos dos mecanismos de participa&ccedil;&atilde;o em processos fisiol&oacute;gicos e patol&oacute;gicos. Foi relatado inclusive, que membros desta familia participam em diferentes processos que levam a apoptose. Apesar disso, o seu controle por membros de outras familias, como por exemplo a BH3, ainda &eacute; insuficientemente determinado <Sup>12</Sup>. </p>      ]]></body>
<body><![CDATA[<p>Os membros da fam&iacute;lia <I>Bcl-2</I> s&atilde;o expressos em uma grande variedade de tecidos fetais, por&eacute;m em adultos, est&aacute; restrito a c&eacute;lulas que est&atilde;o em processo de divis&atilde;o r&aacute;pida e diferencia&ccedil;&atilde;o.  O BCL-2 inibe a via de apoptose preservando principalmente a membrana mitocondrial e inibindo a oligomeriza&ccedil;&atilde;o de Bax/Bak que, ao contr&aacute;rio, liberariam mol&eacute;culas apopt&oacute;ticas <Sup>31</Sup>. Entretanto, Bax por si s&oacute;, &eacute; proapopt&oacute;tico <Sup>12</Sup></p>      <p>Desde a sua identifica&ccedil;&atilde;o em neoplasias de c&eacute;lulas B, a superexpress&atilde;o do BCL-2 vem sendo observada em diferentes tipos de tumores e linhagens celulares, tanto no homem, quanto em animais <Sup>16, 18, 75</Sup>, de forma que o envolvimento dos membros da fam&iacute;lia <I>Bcl-2</I> no c&acirc;ncer tem sido plenamente estabelecido. A associa&ccedil;&atilde;o da express&atilde;o de BCL-2 com a sobreviv&ecirc;ncia tumoral sugere que a superexpress&atilde;o desta prote&iacute;na promove a aquisi&ccedil;&atilde;o de fun&ccedil;&otilde;es associadas a progress&atilde;o tumoral <Sup>63</Sup>. Al&eacute;m disso, sua superexpress&atilde;o e a aus&ecirc;ncia de regula&ccedil;&atilde;o foram observadas em diferentes tipos de tumores <Sup>45</Sup>.</p>      <p>Entretanto, os relatos sobre a sua participa&ccedil;&atilde;o na carcinog&ecirc;nese, bem como a dos membros de sua fam&iacute;lia, s&atilde;o heterog&ecirc;neos. Por um lado, a superexpress&atilde;o confere a muitos tipos de c&eacute;lulas resist&ecirc;ncia a diversos est&iacute;mulos apopt&oacute;ticos <Sup>12</Sup>, atribuindo a c&eacute;lulas tumorais resist&ecirc;ncia aos f&aacute;rmacos e radioterapia <Sup>75</Sup>, al&eacute;m de acelerar a g&ecirc;nese do tumor pela desregula&ccedil;&atilde;o do <I>MYC</I> e outros oncog&ecirc;nes <Sup>16</Sup>. Por outro lado, a superexpress&atilde;o tamb&eacute;m t&ecirc;m-se relacionado com fen&oacute;tipos de baixa malignidade e progn&oacute;stico favor&aacute;vel <Sup>63 </Sup>em camundongos transg&ecirc;nicos. A superexpress&atilde;o de <I>BCL-2</I> promoveu baixa incid&ecirc;ncia de linfomas. No entanto, a perda de alguns dos membros pro-apopt&oacute;ticos como o Bax, tamb&eacute;m acelera o desenvolvimento do tumor <Sup>12 </Sup>(<a href="#g3">Gr&aacute;fico 3</a>).</p>     <p align="center"><a name="g3"></a><img src="img/revistas/cmvz/v9n2/v9n2a12g3.jpg"></p>      <p>Na atualidade, os pesquisadores baseiam-se nestes e em outros achados para propor estrat&eacute;gias terap&ecirc;uticas em diversos tumores. Por exemplo, os recentes progressos na compreens&atilde;o da forma de ativa&ccedil;&atilde;o de Bax/Bak, pode facilitar o desenvolvimento de compostos que regulem a sua atividade, promovendo a sua ativa&ccedil;&atilde;o para o tratamento de c&acirc;ncer, ou inibindo em caso de aumento na taxa de apoptoses <Sup>12</Sup>. </p>      <p>Da mesma maneira, &eacute; possivel tentar modular a terapia baseado em modifica&ccedil;&otilde;es p&oacute;s-traslacionais, como fosforila&ccedil;&atilde;o e ubiquitina&ccedil;&atilde;o, que os membros da familia Bcl-2 acabam sofrendo. Em regra, a fosforila&ccedil;&atilde;o do Bcl-2, altera a sua conforma&ccedil;&atilde;o e incrementa a uni&atilde;o do Bcl-2 ao BAK e BID, tornando as c&eacute;lulas mais refrat&aacute;rias &agrave; quimioterapia <Sup>12</Sup>.</p>      <p>Desta forma, pesquisar a express&atilde;o de genes e prote&iacute;nas desta fam&iacute;lia no TVT, poder&aacute; trazer informa&ccedil;&otilde;es importantes para a abordagem cl&iacute;nica do tumor, assim como promover subs&iacute;dio para novas pesquisas, tanto para este tumor como para os outros tipos de neoplasias. </p>     <p><b>Considera&ccedil;&otilde;es finais</b></p>     <p>No intuito de identificar melhor o perfil de express&atilde;o dos genes <I>MDR-1</I> (glicoprote&iacute;na-p), <I>TP53, BCL-2, BAX</I>, entre outros, h&aacute; uma necessidade de aprofundar nas pesquisas sobre o TVT. Da mesma maneira, torna-se necess&aacute;rio se obter informa&ccedil;&otilde;es relevantes para identificar poss&iacute;veis rela&ccedil;&otilde;es com a express&atilde;o desses genes, buscando aprimorar o tipo de progn&oacute;stico, terapia e compreender o comportamento biol&oacute;gico da neoplasia, auxiliando consequentemente no estabelecimento de um protocolo terap&ecirc;utico adequado para tumores com diferentes graus de agressividade. </p> <hr>     <p><b>Refer&ecirc;ncias</b></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>1.	Adorno M, Cordenonsi M, Montagner M, Wong C, Hann B, <I>et al</I>. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137(1): 87- 98.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000083&pid=S1900-9607201400020001200001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>2.	Amaral AS, Ferreira I, Colodel MM, f&aacute;vero Dm, rocha ns. DNA damage in canine transmissible venereal tumor. Rev Lus Ci&ecirc;n Med Vet 2011; 4: 1- 5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000085&pid=S1900-9607201400020001200002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>3.	Amaral AS, Gaspar LF, Bassini-Silva S, Rocha NS. Cytological diagnostic of transmissible venereal tumor in the Botucatu region, Brazil (descriptive study: 1994-2003). Rev Port Ci&ecirc;n Vet 2004; 99(551): 167-171.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000087&pid=S1900-9607201400020001200003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>4.	Amaral AS, Bassani-Silva S, Ferreira I, Fonseca LS, Andrade FH, <I>et al</I>. Cytomorphological characterization of transmissible canine venereal tumor. Rev Port Ci&ecirc;n Vet 2007; 103: 563-564.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000089&pid=S1900-9607201400020001200004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>5.	Andrade SMF. Antineoplasicos. In: Andrade SMF. Manual de terap&ecirc;utica veterin&aacute;ria<B><I>.</I></B>3&ordf; ed. S&atilde;o Paulo: ROCA, 2008. p. 206-209.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000091&pid=S1900-9607201400020001200005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>6.	Athanasius EC, Kene RO, Anyanwu HC. Comparative efficacy of surgery, vincristine sulphate and combined therapy of levamisole and Bacille Calmette Guerin vaccine in the treatment of transmissible venereal tumour-infected dogs. Comp Clin Pathol 2013; p.1-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000093&pid=S1900-9607201400020001200006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>7.	Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999; 55(1): 48-63.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000095&pid=S1900-9607201400020001200007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>8.	Bergman PJ, Ogilve GK, Powers BE. Monoclonalantibody C219 immunochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Inter Med 1996; 10(6): 354-359.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000097&pid=S1900-9607201400020001200008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>9.	Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr Cancer Drug Targets 2013; 13(3): 326-346.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000099&pid=S1900-9607201400020001200009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>10.	Cadwel C, Zambetti GP. Effects of wild-types p53 tumour suppressor activity and mutant p53 gain-of function on cell grown. Gene 2001; 277(1-2): 15-30.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000101&pid=S1900-9607201400020001200010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>11.	Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2(9): 647-656.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000103&pid=S1900-9607201400020001200011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>12.	Czabotar PE, Lessene G, Strasser A, Adams MJ. Control of apoptosis by the BCL&#8209;2 protein family: implications for physiology and therapy.  Nat Rev Mol Cell Biol 2014; 15(1): 49-63.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000105&pid=S1900-9607201400020001200012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>13.	Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death - Review. Annu Rev Immunol 1998; 16:395-419.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000107&pid=S1900-9607201400020001200013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>14.	Choi YK,  Kim CJ. Sequence analysis of canine LINE-1 elements and p53 in canine transmissible venereal tumor. J Vet Sci 2002; 3(4): 285-292.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000109&pid=S1900-9607201400020001200014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>15.	Das U, Das AK. Review of canine transmissible venereal sarcoma. Vet Res Commun 2000; 24(8): 545-556.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000111&pid=S1900-9607201400020001200015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>16.	Delfino AB. O envolvimento de genes e prote&iacute;nas na regula&ccedil;&atilde;o da apoptose - carcinog&ecirc;nese. Rev Bras Cancerol 1997; 43(3): 173-186.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000113&pid=S1900-9607201400020001200016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>17.	Er&uuml;nal-Maral N, Findik M, Asalan S. Use of exfoliative cytology for diagnosis of transmissible venereal tumour and controlling the recovery period in the bitch. Dtsch Tier&auml;rztl Wochenschr 2000; 107(5): 175-180.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000115&pid=S1900-9607201400020001200017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>18.	Fett-Conte A, Salles AB. A import&acirc;ncia do gene p53 na carcinog&ecirc;nes humana. Rev Bras Hematol Hemoter 2002; 24(2): 85-89.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000117&pid=S1900-9607201400020001200018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p> 19.	Ferreira AJ,  Jaggy A,  Varej&atilde;o AP,  Ferreira  ML,   Correia, JM, <I>et al</I>. Brain and ocular metastases from a transmisible venereal tumour in a dog. J Small Anim Pract 2000; 41(4): 165-168.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000119&pid=S1900-9607201400020001200019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>20.	Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinog&eacute;nesis and the treatment of cancer. Apoptosis 2009; 14(4): 584-596.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000121&pid=S1900-9607201400020001200020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>21.	Ganguly B, Das U,  Das K. Canine transmissible venereal tumour: a review. Vet Comp Onc 2013; 11(4): 1-12.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000123&pid=S1900-9607201400020001200021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>22.	Gaspar LF. Caracteriza&ccedil;&atilde;o citomorfol&oacute;gica do tumor ven&eacute;reo transmiss&iacute;vel canino correlacionada com danos citogen&eacute;ticos, taxa de prolifera&ccedil;&atilde;o e resposta cl&iacute;nica &agrave; quimioterapia. Tese de doutorado, Faculdade de Medicina Veterin&aacute;ria e Zootecnia, Universidade Estadual Paulista, Botucatu, 2005. 143 p.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000125&pid=S1900-9607201400020001200022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>23.	Gaspar LF, Amaral AS, Bassani-Silva S, Rocha NS. Imunorreatividade &agrave; glicoprote&iacute;na-p nos diferentes tipos citomorfol&oacute;gicos de tumor ven&eacute;reo transmiss&iacute;vel canino. Vet em Foco 2009; 6(2): 140-146.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000127&pid=S1900-9607201400020001200023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>24.	Gaspar LF, Ferreira I, Colodel MM, Brand&atilde;o CV, Rocha NS. Spontaneus canine transmissible venereal tumor: cell morphology and influence on p-glycoprotein expression. Turk J Vet Anim Sci 2010; 34(5): 447-454.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000129&pid=S1900-9607201400020001200024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>25.	Harris C, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329(18): 1318-1327.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000131&pid=S1900-9607201400020001200025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>26.	Heinlein C, Krepulat F, Lohler J, Speidel D, Deppert W, <I>et al</I>. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 2008; 122(8), 1701-1709.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000133&pid=S1900-9607201400020001200026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>27.	Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, <I>et al</I>. Very important pharmacogene summary: ABCB1 (MDR1, Pglycoprotein). Pharmacogenet. Genomics 2011; 21(3): 152-161.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000135&pid=S1900-9607201400020001200027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>28.	Kunakornsawat S, Yippaditr W, Jamjan N, Bootcah R, Netramai S, <I>et al</I>. Surgical correction of transmissible venereal tumor with vincristineresistance using episiotomy and vulvo vagino plasty in female and subtotal penile amputation and scrotal ablation in male dogs. In Proceeding of 48th Kasetsart University Annual Conference: Veterinary Medicine. 2010; Feb 3-5, Bangkok, Thailand, 191-200.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000137&pid=S1900-9607201400020001200028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>29.	Kanayan N, Okuda N, Toyama N, Oikawa T, Inokuma H, <I>et al</I>. Detection of the anti-P53 antibodies in dogs with tumors. J Vet Med Sci 2002; 64(11): 973-979.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000139&pid=S1900-9607201400020001200029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>30.	Kirchoff N, Nohr B. Spinal metastasis of a canine transmissible venereal tumor. Kleintierpraxis 1994; 39(11): 797-798.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000141&pid=S1900-9607201400020001200030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>31.	Kirkin V, Joof S, Zorning M. The role of Bcl-2 family members in tumorigenesis. Biochem Bioph Act 2003; 16(44): 229-249.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000143&pid=S1900-9607201400020001200031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>32.	Lacroix M, Toillon RA, Leclercq, G. p53 and breast cancer, an update. Endocr Relat Cancer 2006; 13(2): 293-325.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000145&pid=S1900-9607201400020001200032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>33.	Lee JJ, Hughes CS, Fine RL, Page RL. P-glycoprotein expression in canine lymphoma. Cancer 1996; 77(9): 1892-1898.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000147&pid=S1900-9607201400020001200033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->  </p>     <!-- ref --><p>34.	Macleod RJ. MDR-1, Bcl-xL, H. pylori, and Wnt/b-catenin signalling in the adult stomach: how much is too much?. Laboratory Investigation 2012; 92(12): 1670-1673.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000149&pid=S1900-9607201400020001200034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>35.	Marchal T, Chabanne L, Kaplanski C, Rigal  D, Magnol JP. Immunophenotype of the canine transmissible venereal tumour. Vet Immunol Immunop 1997; 57(1-2):1-11.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000151&pid=S1900-9607201400020001200035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>36.	Maia RC, Rumjanek VM. Mecanismos moleculares de resist&ecirc;ncia a m&uacute;ltiplas drogas. In: Ferreira CG, Rocha JC. Oncologia molecular. S&atilde;o Paulo: Atheneu; 2004. p. 113-122.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000153&pid=S1900-9607201400020001200036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>37.	Mealey KL, Barhoumi R, Rogers K, Kochevar DT. Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Let 1998; 126(2): 187-192.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000155&pid=S1900-9607201400020001200037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>38.	Menendez D, Inga A, Resnick MA. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 2006; 26(6): 2297-308.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000157&pid=S1900-9607201400020001200038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>39.	Mendelsohn J, Howley I, Thompson G. The molecular basis of cancer. 3rd ed. Saunders, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000159&pid=S1900-9607201400020001200039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>40.	Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, <I>et al</I>. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell., v.11, p. 577-590, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000161&pid=S1900-9607201400020001200040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>41.	Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, <I>et al</I>. The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1 a suppresses polyp formation in Apc (Min/+) mice. Carcinogenesis 2003; 24(7): 1219-1224.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000163&pid=S1900-9607201400020001200041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>42.	Montoya FL, Pedraza FJ, Grandi F, Rocha N. Cytologic subtypes of canine transmissible venereal tumor. Vet Clin Pathol 2012; 41(1):  4-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000165&pid=S1900-9607201400020001200042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>43.	Montoya FL, Pedraza FJ, Monteiro S, Brand&atilde;o CV, Rocha NS. Cytological and clinical staging of transmissible venereal tumour at the Veterinary Hospital of Botucatu. Rev Vet Zoot 2014; in press.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000167&pid=S1900-9607201400020001200043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>44.	Mozos E, M&eacute;ndez A, G&oacute;mez-Villamandos JC, Mart&iacute;n de las mulas J, P&eacute;rez J. lmmunohistochemical characterization of canine transmissible venereal tumor. Vet Path 1996; 33(3): 257-263.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000169&pid=S1900-9607201400020001200044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>45.	Moro JV, Tinucci-Costa M, Silveira AC, Gerardi DG, Alessi AC. Reactivity of p53 protein in canine transmissible venereal tumor. Arq Bras Med Vet Zootec 2010; 62(2): 318-323.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000171&pid=S1900-9607201400020001200045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>46.	Muller PA, Caswell PT, Doyle B, Iwanicki M, Tan E, <I>et al</I>. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139(7): 1327-1341.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000173&pid=S1900-9607201400020001200046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>47.	Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192(2): 209-218.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000175&pid=S1900-9607201400020001200047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>48.	Murchison PE, Wedge DC, Alexandrov LB, Fu B,  Martincorena I, <I>et al</I>. Transmissable Dog Cancer Genome Reveals the Origin and History of an Ancient Cell Lineage. Science 2014; 343( 6169): 437-440.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000177&pid=S1900-9607201400020001200048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>49.	Nielsen SW, Kennedy PC. Tumors of the genital systems. In: Moulton JE. Tumors in domestic animals. 3&ordf; ed. Los Angeles: London; 2000. p. 479-517.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000179&pid=S1900-9607201400020001200049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>50.	Oliveira DK, Quessada AM, Medeiros SM, Lima CF, Dos Santos LS, <I>et al</I>. Transmissible Venereal Tumor Treated with Autohemotherapy. Acta Scientiae Veterinariae 2013; 41:1107.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000181&pid=S1900-9607201400020001200050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>51.	Ozaki T, Nakagawara A. p53: The Attractive Tumor Suppressor in the Cancer Research Field. J Biomed Biotechnol 2011; &#91;acesso: 14 fevereiro de 2014&#93;. <a href="http://www.hindawi.com/journals/bmri/2011/603925/" target="_blank">http://www.hindawi.com/journals/bmri/2011/603925/</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000183&pid=S1900-9607201400020001200051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>52.	Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2011; 2(4): 466-474.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000184&pid=S1900-9607201400020001200052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>53.	Rogers KS. Transmissible venereal tumour. Compend Contin Educ Pract Vet 1997; 19(9): 1036-1045.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000186&pid=S1900-9607201400020001200053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>54.	Rogers KS, Walker MA, Dillon HB. Transmissible venereal tumor: a retrospective study of 29 cases. J Am Anim Hosp Assoc 1998; 34(6): 463- 470.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000188&pid=S1900-9607201400020001200054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>55.	Said RA, Silva LF, Albuquerque A, Sousa- Neta, EM, Lavinsky MO. Efficacy and side effects of vincristine sulfate treatment on canine transmissible venereal tumor. In Proceeding of the 34th World Small Animal Veterinary Association, Sao Paulo, 2009. &#91;acesso: 10 de Fevereiro de 2014&#93;.  <a href="http://s.plx?CID =WSAVA2009&amp;Category=&amp;PID=5379 4&amp;0=Generic" target="_blank">http://s.plx?CID =WSAVA2009&amp;Category=&amp;PID=5379 4&amp;0=Generic</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000190&pid=S1900-9607201400020001200055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>56.	Santos FG, Vasconcelos AC, Nunes JE, Cassali GD, Paix&atilde;o TA, Moro L. O tumor ven&eacute;reo transmiss&iacute;vel canino - aspectos gerais e abordagens moleculares (revis&atilde;o de literatura). Bioscience J 2005; 21(3): 41- 53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000192&pid=S1900-9607201400020001200056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>57.	Serv&iacute;n SA, Mart&iacute;nez S, Alarcon EC, Fajardo R.  TP53 Polymorphisms allow for genetic sub-grouping of the canine transmissible venereal tumor. J Vet Sci 2009; 10(4): 353- 355.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000194&pid=S1900-9607201400020001200057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>58.	Siddle HV,  Kaufman J.  A tale of two tumours: Comparison of the immune escape strategies of contagious cancers. Mol Immunol 2013; 55(2): 190-193.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000196&pid=S1900-9607201400020001200058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>59.	Soto CV. Caracterizaci&oacute;n del efecto anticanceroso e identificaci&oacute;n de dianas moleculares de principios activos procedentes de <I>serrata marcescens. </I>Tesis de doctoral, Universidad de Barcelona, Barcelona, Espa&ntilde;a, 2007. 252 p.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000198&pid=S1900-9607201400020001200059&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>60.	Soussi T, Beroud C. "Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Can 2001; 1(3): 233-240.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000200&pid=S1900-9607201400020001200060&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>61.	Sousa J, Saito V, Nardi B, Rodaski S, Guerios S, Bacila M. Caracter&iacute;sticas e incid&ecirc;ncia do tumor ven&eacute;reo transmiss&iacute;vel (TVT) em c&atilde;es e efici&ecirc;ncia da quimioterapia e outros tratamentos. Arch Vet Sci Curitiba 2000; 5: 41- 48.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000202&pid=S1900-9607201400020001200061&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>62.	Stockmann D, Ferrari H, Andrade A, Cardoso T, Luvizotto M. Detection of the tumour suppressor gene <I>TP53 </I>and expression of p53, Bcl-2 and p63 proteins in canine transmissible venereal tumor. Vet Comp Oncol 2011a; 9(4): 1- 9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000204&pid=S1900-9607201400020001200062&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>63.	Stockmann D, Ferrari H, Andrade A, Lopes A, Cardoso T, Luvizotto M. Canine Transmissible Venereal Tumors: Aspects Related to Programmed Cell Death. Braz J Vet Pathol 2011b; 4(1): 67- 75.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000206&pid=S1900-9607201400020001200063&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>64.	Sudjaidee P, Theewasutrakul P, Techarungchaikul S,  Ponglowhapanl S, Chatdarong K. Treatment of canine transmissible venereal tumor using vincristine sulfate combined with l-asparaginase in clinical vincristine-resistant cases: a case report. Thai J Vet Med 2012; 42(1): 117- 122.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000208&pid=S1900-9607201400020001200064&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>65.	Suzuki K, Matsubara H. Recent Advances in p53 Research and Cancer Treatment. J Biomed Biotechnol 2011; 2-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000210&pid=S1900-9607201400020001200065&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>66.	Szak&aacute;cs G, Paterson J, Ludwig J, Booth-genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat rev 2006; 5(3): 219- 234.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000212&pid=S1900-9607201400020001200066&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>67.	Thomas H, Coley H. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p -glycoprotein. Canc Cont 2003; 10(2): 159- 165.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000214&pid=S1900-9607201400020001200067&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>68.	Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, <I>et al</I>. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006; 281(13): 8600-8606.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000216&pid=S1900-9607201400020001200068&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>69.	Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol 2012; 16(1): 102-108.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000218&pid=S1900-9607201400020001200069&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>70.	Varaschin M, Wouters V, Soares T, Tokura V, Dias M. Tumor ven&eacute;reo transmiss&iacute;vel canino na regi&atilde;o de Alfenas, Minas Gerais: formas de apresenta&ccedil;&atilde;o cl&iacute;nicopatol&oacute;gicas. Rev Cl&iacute;n Vet 2001; 32: 40- 48.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000220&pid=S1900-9607201400020001200070&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>71.	V&aacute;zquez M, Mart&iacute;nez S, Alarc&oacute;n C, lagunes L, Fajardo R. The T963C mutation of TP53 gene does not participate in the clonal origin of canine TVT. Vet Res Commun 2008; 32(2): 187-191.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000222&pid=S1900-9607201400020001200071&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>72.	Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012; 33(11): 2007- 2017.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000224&pid=S1900-9607201400020001200072&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>73.	Wang L, Song Y, Zheng W, Jiang L, Ma L. The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies. Cancer Cell International 2013; 13(1): 46 .    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000226&pid=S1900-9607201400020001200073&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>74.	Warr JR, Bamford A, Quinn DM. The preferential induction of apoptosis in multidrug resistant B cells by 5-fluouracil. Cancer Lett 2002; 175: 39-44.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000228&pid=S1900-9607201400020001200074&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>75.	Zhou H, Chen J, Meagher J, Yang C, Aguilar A, <I>et al</I>. Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold. J Med  Chem 2012; 55(10): 4664-4682.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000230&pid=S1900-9607201400020001200075&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>76.	Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy Nature 2008; 7: 979-987.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000232&pid=S1900-9607201400020001200076&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>  </font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adorno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cordenonsi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montagner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2009</year>
<volume>137</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>87- 98</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Colodel]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[fávero]]></surname>
<given-names><![CDATA[Dm]]></given-names>
</name>
<name>
<surname><![CDATA[rocha]]></surname>
<given-names><![CDATA[ns]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[DNA damage in canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Rev Lus Ciên Med Vet]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>1- 5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Bassini-Silva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytological diagnostic of transmissible venereal tumor in the Botucatu region, Brazil (descriptive study: 1994-2003)]]></article-title>
<source><![CDATA[Rev Port Ciên Vet]]></source>
<year>2004</year>
<volume>99</volume>
<numero>551</numero>
<issue>551</issue>
<page-range>167-171</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Bassani-Silva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytomorphological characterization of transmissible canine venereal tumor]]></article-title>
<source><![CDATA[Rev Port Ciên Vet]]></source>
<year>2007</year>
<volume>103</volume>
<page-range>563-564</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[SMF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antineoplasicos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[SMF]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de terapêutica veterinária]]></source>
<year>2008</year>
<edition>3</edition>
<page-range>206-209</page-range><publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
<publisher-name><![CDATA[ROCA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Athanasius]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Kene]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Anyanwu]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparative efficacy of surgery, vincristine sulphate and combined therapy of levamisole and Bacille Calmette Guerin vaccine in the treatment of transmissible venereal tumour-infected dogs]]></article-title>
<source><![CDATA[Comp Clin Pathol]]></source>
<year>2013</year>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Attardi]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Jacks]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of p53 in tumour suppression: lessons from mouse models]]></article-title>
<source><![CDATA[Cell Mol Life Sci]]></source>
<year>1999</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-63</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ogilve]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Powers]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monoclonalantibody C219 immunochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma]]></article-title>
<source><![CDATA[J Vet Inter Med]]></source>
<year>1996</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>354-359</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Binkhathlan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lavasanifar]]></surname>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives]]></article-title>
<source><![CDATA[Curr Cancer Drug Targets]]></source>
<year>2013</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>326-346</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cadwel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zambetti]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of wild-types p53 tumour suppressor activity and mutant p53 gain-of function on cell grown]]></article-title>
<source><![CDATA[Gene]]></source>
<year>2001</year>
<volume>277</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>15-30</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cory]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Bcl2 family: regulators of the cellular life-or-death switch]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2002</year>
<volume>2</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>647-656</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Czabotar]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Lessene]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Strasser]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Control of apoptosis by the BCL&#8209;2 protein family: implications for physiology and therapy]]></article-title>
<source><![CDATA[Nat Rev Mol Cell Biol]]></source>
<year>2014</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-63</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Korsmeyer]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[BCL-2 family: regulators of cell death - Review]]></article-title>
<source><![CDATA[Annu Rev Immunol]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>395-419</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sequence analysis of canine LINE-1 elements and p53 in canine transmissible venereal tumor]]></article-title>
<source><![CDATA[J Vet Sci]]></source>
<year>2002</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>285-292</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Review of canine transmissible venereal sarcoma]]></article-title>
<source><![CDATA[Vet Res Commun]]></source>
<year>2000</year>
<volume>24</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>545-556</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Delfino]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[O envolvimento de genes e proteínas na regulação da apoptose - carcinogênese]]></article-title>
<source><![CDATA[Rev Bras Cancerol]]></source>
<year>1997</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>173-186</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erünal-Maral]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Findik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Asalan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of exfoliative cytology for diagnosis of transmissible venereal tumour and controlling the recovery period in the bitch]]></article-title>
<source><![CDATA[Dtsch Tierärztl Wochenschr]]></source>
<year>2000</year>
<volume>107</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>175-180</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fett-Conte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salles]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[A importância do gene p53 na carcinogênes humana]]></article-title>
<source><![CDATA[Rev Bras Hematol Hemoter]]></source>
<year>2002</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>85-89</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jaggy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Varejão]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Correia]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brain and ocular metastases from a transmisible venereal tumour in a dog]]></article-title>
<source><![CDATA[J Small Anim Pract]]></source>
<year>2000</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>165-168</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frenzel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grespi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chmelewskij]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Villunger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Bcl2 family proteins in carcinogénesis and the treatment of cancer]]></article-title>
<source><![CDATA[Apoptosis]]></source>
<year>2009</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>584-596</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ganguly]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Canine transmissible venereal tumour: a review]]></article-title>
<source><![CDATA[Vet Comp Onc]]></source>
<year>2013</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterização citomorfológica do tumor venéreo transmissível canino correlacionada com danos citogenéticos, taxa de proliferação e resposta clínica à quimioterapia]]></source>
<year>2005</year>
<page-range>143</page-range><publisher-name><![CDATA[Faculdade de Medicina Veterinária e Zootecnia, Universidade Estadual Paulista]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Bassani-Silva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Imunorreatividade à glicoproteína-p nos diferentes tipos citomorfológicos de tumor venéreo transmissível canino]]></article-title>
<source><![CDATA[Vet em Foco]]></source>
<year>2009</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>140-146</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Colodel]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Spontaneus canine transmissible venereal tumor: cell morphology and influence on p-glycoprotein expression]]></article-title>
<source><![CDATA[Turk J Vet Anim Sci]]></source>
<year>2010</year>
<volume>34</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>447-454</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hollstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical implications of the p53 tumor-suppressor gene]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1993</year>
<volume>329</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1318-1327</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heinlein]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Krepulat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lohler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Speidel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Deppert]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2008</year>
<volume>122</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1701-1709</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodges]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Markova]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Chinn]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kroetz]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Very important pharmacogene summary: ABCB1 (MDR1, Pglycoprotein)]]></article-title>
<source><![CDATA[Pharmacogenet. Genomics]]></source>
<year>2011</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>152-161</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kunakornsawat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yippaditr]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jamjan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bootcah]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Netramai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Surgical correction of transmissible venereal tumor with vincristineresistance using episiotomy and vulvo vagino plasty in female and subtotal penile amputation and scrotal ablation in male dogs]]></source>
<year>2010</year>
<page-range>191-200</page-range><publisher-name><![CDATA[Proceeding of 48th Kasetsart University Annual Conference: Veterinary Medicine.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanayan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Okuda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Oikawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Inokuma]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of the anti-P53 antibodies in dogs with tumors]]></article-title>
<source><![CDATA[J Vet Med Sci]]></source>
<year>2002</year>
<volume>64</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>973-979</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchoff]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nohr]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Spinal metastasis of a canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Kleintierpraxis]]></source>
<year>1994</year>
<volume>39</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>797-798</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirkin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Joof]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zorning]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of Bcl-2 family members in tumorigenesis]]></article-title>
<source><![CDATA[Biochem Bioph Act]]></source>
<year>2003</year>
<volume>16</volume>
<numero>44</numero>
<issue>44</issue>
<page-range>229-249</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lacroix]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toillon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Leclercq]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[p53 and breast cancer, an update]]></article-title>
<source><![CDATA[Endocr Relat Cancer]]></source>
<year>2006</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>293-325</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Fine]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[P-glycoprotein expression in canine lymphoma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1996</year>
<volume>77</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1892-1898</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macleod]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[MDR-1, Bcl-xL, H. pylori, and Wnt/b-catenin signalling in the adult stomach: how much is too much?]]></article-title>
<source><![CDATA[Laboratory Investigation]]></source>
<year>2012</year>
<volume>92</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1670-1673</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marchal]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chabanne]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplanski]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rigal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Magnol]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunophenotype of the canine transmissible venereal tumour]]></article-title>
<source><![CDATA[Vet Immunol Immunop]]></source>
<year>1997</year>
<volume>57</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maia]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Rumjanek]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Mecanismos moleculares de resistência a múltiplas drogas]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncologia molecular]]></source>
<year>2004</year>
<page-range>113-122</page-range><publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
<publisher-name><![CDATA[Atheneu]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mealey]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Barhoumi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kochevar]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line]]></article-title>
<source><![CDATA[Cancer Let]]></source>
<year>1998</year>
<volume>126</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-192</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menendez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Inga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Resnick]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes]]></article-title>
<source><![CDATA[Mol Cell Biol]]></source>
<year>2006</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2297-308</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendelsohn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Howley]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[The molecular basis of cancer]]></source>
<year>2008</year>
<edition>3</edition>
<publisher-name><![CDATA[Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mihara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Erster]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zaika]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Petrenko]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Chittenden]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[p53 has a direct apoptogenic role at the mitochondria]]></article-title>
<source><![CDATA[Mol. Cell]]></source>
<year></year>
<volume>11</volume>
<page-range>577-590</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mochida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Taguchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Taniguchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuneyoshi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1 a suppresses polyp formation in Apc (Min/+) mice]]></article-title>
<source><![CDATA[Carcinogenesis]]></source>
<year>2003</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1219-1224</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Pedraza]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grandi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytologic subtypes of canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Vet Clin Pathol]]></source>
<year>2012</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-5</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Pedraza]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mozos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Villamandos]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Martín de las mulas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[lmmunohistochemical characterization of canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Vet Path]]></source>
<year>1996</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>257-263</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moro]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Tinucci-Costa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Gerardi]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Alessi]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reactivity of p53 protein in canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Arq Bras Med Vet Zootec]]></source>
<year>2010</year>
<volume>62</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>318-323</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Caswell]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Doyle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Iwanicki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mutant p53 drives invasion by promoting integrin recycling]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2009</year>
<volume>139</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1327-1341</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Vousden]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[p53 and its mutants in tumor cell migration and invasion]]></article-title>
<source><![CDATA[J Cell Biol]]></source>
<year>2011</year>
<volume>192</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>209-218</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murchison]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Wedge]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Alexandrov]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Martincorena]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transmissable Dog Cancer Genome Reveals the Origin and History of an Ancient Cell Lineage]]></article-title>
<source><![CDATA[Science]]></source>
<year>2014</year>
<volume>343</volume>
<numero>6169</numero>
<issue>6169</issue>
<page-range>437-440</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tumors of the genital systems]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Moulton]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Tumors in domestic animals]]></source>
<year>2000</year>
<edition>3</edition>
<page-range>479-517</page-range><publisher-loc><![CDATA[^eLos Angeles Los Angeles]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Quessada]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Medeiros]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Dos Santos]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transmissible Venereal Tumor Treated with Autohemotherapy]]></article-title>
<source><![CDATA[Acta Scientiae Veterinariae]]></source>
<year>2013</year>
<volume>41</volume>
<page-range>1107</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nakagawara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[p53: The Attractive Tumor Suppressor in the Cancer Research Field]]></article-title>
<source><![CDATA[J Biomed Biotechnol]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivlin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Brosh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Oren]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rotter]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.]]></article-title>
<source><![CDATA[Genes Cancer]]></source>
<year>2011</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>466-474</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transmissible venereal tumour]]></article-title>
<source><![CDATA[Compend Contin Educ Pract Vet]]></source>
<year>1997</year>
<volume>19</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1036-1045</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transmissible venereal tumor: a retrospective study of 29 cases]]></article-title>
<source><![CDATA[J Am Anim Hosp Assoc]]></source>
<year>1998</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>463- 470</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Said]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Albuquerque]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa- Neta]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Lavinsky]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy and side effects of vincristine sulfate treatment on canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Proceeding of the 34th World Small Animal Veterinary Association]]></source>
<year>2009</year>
<month>10</month>
<day> d</day>
<publisher-loc><![CDATA[Sao Paulo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Vasconcelos]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Cassali]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Paixão]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Moro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[O tumor venéreo transmissível canino - aspectos gerais e abordagens moleculares (revisão de literatura)]]></article-title>
<source><![CDATA[Bioscience J]]></source>
<year>2005</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>41- 53</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Servín]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcon]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TP53 Polymorphisms allow for genetic sub-grouping of the canine transmissible venereal tumor]]></article-title>
<source><![CDATA[J Vet Sci]]></source>
<year>2009</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>353- 355</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddle]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A tale of two tumours: Comparison of the immune escape strategies of contagious cancers]]></article-title>
<source><![CDATA[Mol Immunol]]></source>
<year>2013</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>190-193</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterización del efecto anticanceroso e identificación de dianas moleculares de principios activos procedentes de serrata marcescens]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soussi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Beroud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Assessing TP53 status in human tumours to evaluate clinical outcome]]></article-title>
<source><![CDATA[Nat Rev Can]]></source>
<year>2001</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>233-240</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Nardi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rodaski]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guerios]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bacila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Características e incidência do tumor venéreo transmissível (TVT) em cães e eficiência da quimioterapia e outros tratamentos]]></article-title>
<source><![CDATA[Arch Vet Sci Curitiba]]></source>
<year>2000</year>
<volume>5</volume>
<page-range>41- 48</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stockmann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Luvizotto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of the tumour suppressor gene TP53 and expression of p53, Bcl-2 and p63 proteins in canine transmissible venereal tumor]]></article-title>
<source><![CDATA[Vet Comp Oncol]]></source>
<year>2011</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1- 9</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stockmann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Luvizotto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Canine Transmissible Venereal Tumors: Aspects Related to Programmed Cell Death]]></article-title>
<source><![CDATA[Braz J Vet Pathol]]></source>
<year>2011</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67- 75</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sudjaidee]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Theewasutrakul]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Techarungchaikul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ponglowhapanl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chatdarong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of canine transmissible venereal tumor using vincristine sulfate combined with l-asparaginase in clinical vincristine-resistant cases: a case report]]></article-title>
<source><![CDATA[Thai J Vet Med]]></source>
<year>2012</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>117- 122</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Matsubara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recent Advances in p53 Research and Cancer Treatment]]></article-title>
<source><![CDATA[J Biomed Biotechnol]]></source>
<year>2011</year>
<page-range>2-7</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Szakács]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ludwig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Booth-genthe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gottesman]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Targeting multidrug resistance in cancer]]></article-title>
<source><![CDATA[Nat rev]]></source>
<year>2006</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>219- 234</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Coley]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p -glycoprotein]]></article-title>
<source><![CDATA[Canc Cont]]></source>
<year>2003</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>159- 165</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomita]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Marchenko]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Erster]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nemajerova]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dehner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2006</year>
<volume>281</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>8600-8606</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsujimura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease]]></article-title>
<source><![CDATA[Clin Exp Nephrol]]></source>
<year>2012</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>102-108</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varaschin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wouters]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tokura]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Tumor venéreo transmissível canino na região de Alfenas, Minas Gerais: formas de apresentação clínicopatológicas]]></article-title>
<source><![CDATA[Rev Clín Vet]]></source>
<year>2001</year>
<volume>32</volume>
<page-range>40- 48</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[lagunes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The T963C mutation of TP53 gene does not participate in the clonal origin of canine TVT]]></article-title>
<source><![CDATA[Vet Res Commun]]></source>
<year>2008</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-191</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walerych]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Napoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Collavin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Del Sal]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The rebel angel: mutant p53 as the driving oncogene in breast cancer]]></article-title>
<source><![CDATA[Carcinogenesis]]></source>
<year>2012</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2007- 2017</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies]]></article-title>
<source><![CDATA[Cancer Cell International]]></source>
<year>2013</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warr]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Bamford]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The preferential induction of apoptosis in multidrug resistant B cells by 5-fluouracil]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2002</year>
<volume>175</volume>
<page-range>39-44</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meagher]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold]]></article-title>
<source><![CDATA[J Med Chem]]></source>
<year>2012</year>
<volume>55</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4664-4682</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vazquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<source><![CDATA[The genetics of the p53 pathway, apoptosis and cancer therapy Nature]]></source>
<year>2008</year>
<page-range>979-987</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
